Monica Mita

12.2k total citations · 2 hit papers
239 papers, 8.2k citations indexed

About

Monica Mita is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Monica Mita has authored 239 papers receiving a total of 8.2k indexed citations (citations by other indexed papers that have themselves been cited), including 144 papers in Oncology, 104 papers in Molecular Biology and 74 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Monica Mita's work include Cancer Treatment and Pharmacology (49 papers), PI3K/AKT/mTOR signaling in cancer (37 papers) and Lung Cancer Treatments and Mutations (28 papers). Monica Mita is often cited by papers focused on Cancer Treatment and Pharmacology (49 papers), PI3K/AKT/mTOR signaling in cancer (37 papers) and Lung Cancer Treatments and Mutations (28 papers). Monica Mita collaborates with scholars based in United States, Spain and France. Monica Mita's co-authors include Alain C. Mita, Francis J. Giles, Steffan T. Nawrocki, Eric K. Rowinsky, Anthony W. Tolcher, Kamalesh K. Sankhala, Devalingam Mahalingam, Amita Patnaik, Esha Sachdev and Chris H. Takimoto and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Monica Mita

231 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics

2008 638 citations Alain C. Mita, Monica Mita et al. Clinical Cancer Research profile →
Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

2019 314 citations Monica Mita et al. profile →

Peers

Countries citing papers authored by Monica Mita

Since Specialization

Citations

This map shows the geographic impact of Monica Mita's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monica Mita with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monica Mita more than expected).

Fields of papers citing papers by Monica Mita

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monica Mita. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monica Mita. The network helps show where Monica Mita may publish in the future.

Co-authorship network of co-authors of Monica Mita

This figure shows the co-authorship network connecting the top 25 collaborators of Monica Mita. A scholar is included among the top collaborators of Monica Mita based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monica Mita. Monica Mita is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2 2025 ·Cancer Research Communications ·Monica Mita, (unknown), (unknown), (unknown), (unknown), (unknown), David J. Browning, (unknown), (unknown), (unknown), Peter Cornelius	0
2	Final outcomes analysis of the cell product SQZ‐PBMC‐HPV Phase 1 trial in incurable HPV16+ solid tumors shows improved overall survival in patients with increased CD8+ T cell tumor infiltration 2024 ·Molecular Carcinogenesis ·Alice N. Weaver, Wade T. Iams, Jong Chul Park, Monica Mita, Udo Holtick, Michael S. Gordon, Kerry J. Rodabaugh, Neesha C. Dhani, Prakash Neupane, Matthew H. Taylor, (unknown), (unknown), Nathan R. Miselis, Scott Loughhead, Marshelle Warren, Howard Bernstein, Jens Peter Klußmann, Joaquina Baranda, Antonio Jimeno	2
3	Abstract PO4-18-07: A dose escalation and cohort expansion study of the CDK9 inhibitor KB-0742 in triple negative breast cancer and transcriptionally addicted relapsed or refractory solid tumors 2024 ·Cancer Research ·Monica Mita, Alain C. Mita, Miguel A. Villalona‐Calero, Noah Federman, Drew Rasco, David R. Spigel, Jia Luo, Gregory M. Coté, Richard E. Cutler, Pavan Kumar, Crystal MacKenzie, Charles Y. Lin, Jorge DiMartino, Elizabeth Olek, Brian A. Van Tine	1
4	627 The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma 2023 ·SHILAP Revista de lepidopterología ·Jordi Rodon, Marya Chaney, Justine V. Cohen, Tina Garyantes, (unknown), Jeffrey J. Ishizuka, Alain C. Mita, Monica Mita, Carolyn Y. Muller, Christopher A. Natale, Marlana Orloff, Kyriakos P. Papadopoulos, Sapna P. Patel, Alexander N. Shoushtari	0
5	AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers 2023 ·npj Precision Oncology ·Maysa Abu‐Khalaf, (unknown), Christos Hatzis, Elisa Baldelli, (unknown), (unknown), William M. Sikov, Monica Mita, Neelima Denduluri, (unknown), Daniel Zelterman, Lance A. Liotta, (unknown), (unknown), Emanuel F. Petricoin, Mariaelena Pierobon	21
6	Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer 2021 ·Journal of Hematology & Oncology ·Apostolia M. Tsimberidou, (unknown), Dejan Juric, Claire F. Verschraegen, Amy Weise, John Sarantopoulos, Gilberto Lopes, John Nemunaitis, Monica Mita, Haeseong Park, Barbara Ellers‐Lenz, Hui Tian, (unknown), (unknown), Razelle Kurzrock	20
7	A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis Proteins, in Adults with Advanced Cancers or Lymphoma 2020 ·Clinical Cancer Research ·Monica Mita, Patricia LoRusso, Kyriakos P. Papadopoulos, Michael S. Gordon, Alain C. Mita, Roberta Ferraldeschi, Harold Keer, Aram Oganesian, Xiang Yao Su, Simone Jueliger, Anthony W. Tolcher	30
8	Comparison of Large, Medium, and Small Solid Tumor Gene Panels for Detection of Clinically Actionable Mutations in Cancer 2020 ·Targeted Oncology ·Eric Vail, Jianbo Song, Jing Xu, (unknown), (unknown), (unknown), Rhona Schreck, (unknown), Wenjuan Zhang, Serhan Alkan, Alain C. Mita, Monica Mita, Robert A. Figlin, David M. Engman, Jean Lopategui	9
9	First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy 2019 ·SHILAP Revista de lepidopterología ·Pamela N. Münster, Monica Mita, Amit Mahipal, John Nemunaitis, Christophe Massard, Tom Mikkelsen, Cristina Cruz, Luis Paz‐Ares, Manuel Hidalgo, Dana E. Rathkopf, (unknown), (unknown), Barbara Eichhorst, Timothy F. Cloughesy, (unknown), Li S, Heather K. Raymon, (unknown), Kristen Hege, (unknown)	1
10	Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors 2016 ·Clinical Cancer Research ·Daniel D. Von Hoff, Monica Mita, Ramesh K. Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia LoRusso, Howard A. Burris, Lowell L. Hart, Susan C. Low, Donald M. Parsons, Stephen E. Zale, Jason M. Summa, Hagop Youssoufian, Jasgit C. Sachdev	215
11	First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn D. Britten, (unknown), Monica Mita, Vali Papadimitrakopoulou, (unknown), Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, (unknown), Hong Lü, Stuart Bailey, (unknown), Udai Banerji	119
12	Safety and Pharmacokinetics of Ganitumab (AMG 479) Combined with Sorafenib, Panitumumab, Erlotinib, or Gemcitabine in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Lee S. Rosen, Igor Puzanov, Gregory Friberg, Emily Chan, Yuying C. Hwang, Hongjie Deng, Jill Gilbert, Devalingam Mahalingam, Ian McCaffery, (unknown), Alain C. Mita, Monica Mita, Marilyn Mulay, (unknown), Min Zhu, John Sarantopoulos	30
13	Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin 2011 ·Clinical Cancer Research ·Anthony W. Tolcher, Christopher J. Sweeney, K. Papadopoulos, Amita Patnaik, E. Gabriela Chiorean, Alain C. Mita, Kamalesh K. Sankhala, Eric S. Furfine, Jochem Gokemeijer, Lisa Iacono, Cheryl A. Eaton, Bruce A. Silver, Monica Mita	67
14	A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies 2009 ·Clinical Cancer Research ·Sanjay Goel, Alain C. Mita, Monica Mita, Eric K. Rowinsky, Quincy S. Chu, Nancy Wong, Christopher DesJardins, Fang Fang, Mendel Jansen, Dale E. Shuster, Sridhar Mani, Chris H. Takimoto	121
15	Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma 2008 ·Clinical Cancer Research ·Leigh Ellis, Yan Pan, Gordon K. Smyth, Daniel J. George, Chris McCormack, (unknown), Monica Mita, Joachim Beck, Howard A. Burris, Gail Ryan, Peter Atadja, Dale Butterfoss, Margaret Dugan, Kenneth W. Culver, Ricky W. Johnstone, H. Miles Prince	244
16	Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies 2008 ·Journal of Clinical Oncology ·Monica Mita, Alain C. Mita, Quincy S. Chu, Eric K. Rowinsky, Gerald J. Fetterly, (unknown), Amita Patnaik, Lesley Mathews, Alejandro D. Ricart, Theresa A. Mays, Heather Knowles, Victor M. Rivera, (unknown), Camille L. Bedrosian, Anthony W. Tolcher	227
17	A phase I and pharmacokinetic study of a CanAg-targeted immunoconjugate, HuC242-DM4, in patients with CanAg-expressing solid tumors 2007 ·Molecular Cancer Therapeutics ·Kamalesh K. Sankhala, Alain C. Mita, Alejandro D. Ricart, Monica Mita, (unknown), Leslie Wood, John Sarantopoulos, Chris H. Takimoto, Amita Patnaik, Albert Qin, S. Zildjian, (unknown)	2
18	Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas 2007 ·Molecular Cancer Therapeutics ·Patricia LoRusso, Lorrin Yee, K. Papadopoulos, (unknown), (unknown), (unknown), Elisabeth I. Heath, G. Kenneth Lloyd, (unknown), Saskia Neuteboom, (unknown), G. Cropp, Matthew A. Spear, Monica Mita	1
19	Phase I study of BMS-247550, an epothilone B analog, administered weekly for 3 weeks followed by a one-week break in patients (pts) with advanced malignancies 2006 ·Cancer Research ·Alejandro D. Ricart, Anthony W. Tolcher, Quincy S. Chu, Johann S. de Bono, Muralidhar Beeram, Desirée Hao, Monica Mita, Alain C. Mita, Geoffrey R. Weiss, Chris H. Takimoto, Eric K. Rowinsky	3
20	Phase II Trial of Paclitaxel–Epirubicin in Patients With Recurrent Soft-Tissue Sarcoma 2002 ·American Journal of Clinical Oncology ·Xavier Pivot, Christine Chevreau, Didier Cupissol, Alain Lortholary, (unknown), Jean‐Christophe Eymard, Jacques‐Olivier Bay, Marie‐Christine Baranzelli, Monica Mita, (unknown), J. Savary, Antoine Thyss	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact